The range of therapeutic efficacy of atypical antipsychotics: a critical evaluation

Dimova, Aleksandra

doi:10.1016/s0306-9877(03)00157-9

Cited by 7 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Olanzapine and aripiprazole also have recently been FDA‐approved for long‐term treatment of bipolar disorder 13. In addition, in both the United States and Europe, modern APDs are increasingly used for a variety of other indications, including psychotic mood disorders, aggression, and sometimes even for anxiety and insomnia, including in populations where adverse effects are of special concern, such as children, adolescents, and the elderly 114–116…”

Section: Is Risk Of Td Declining?mentioning

confidence: 99%

“…Use of second‐generation APDs rose rapidly in the 1990s to account for 70% of hospital prescriptions for APDs by 1999, and an even higher proportion currently 13, 16, 114. A substantial proportion of the increasingly broad applications of modern APDs is for off‐label indications prescribed by psychiatrists, primary care providers, and other physicians, which may or may not be supported by controlled trials or even uncontrolled trials or case reports 13, 16, 115, 116. Such uses of these versatile drugs are encouraged by their apparent low risk of acute EPS 16.…”

Section: Is Risk Of Td Declining?mentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?

2006

View full text Add to dashboard Cite

Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.

show abstract

Section: Is Risk Of Td Declining?mentioning

confidence: 99%

Section: Is Risk Of Td Declining?mentioning

confidence: 99%

Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?

2006

View full text Add to dashboard Cite

show abstract

“…Combination therapy with lithium or divalproex (including a variety of its salts or valproic acid) plus an antipsychotic, preferably an atypical agent due to its more benign side-effect profile (Dimova, 2003;Sussman, 2002), is recommended as a first-line approach to treatment of severe manic or mixed episodes in patients with bipolar disorder (American Psychiatric Association, 2002;Goodwin, 2003;Grunze et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Open‐label steady‐state pharmacokinetic drug interaction study on co‐administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder

Winter

DeVane

Figueroa³

et al. 2007

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…the presence of a physical injury or disease). In fact, substantial debate surrounds the definition, treatment, and even existence of the fundamental notion ''mental illness'' (Breggin, 1998;Dimova, 2003;Szasz, 1988;Tien & Gallo, 1997). Claims about insight are particularly difficult to substantiate because they involve the person's ''subjective report of his or her internal state'' (Keefe, 1998, p. 159).…”

Section: Problems Faced By the Review Bodymentioning

confidence: 99%

Interpretive flexibility: why doesn't insight incite controversy in mental health law?

Diesfeld

Sjöström²

2006

Behavioral Sci & The Law

View full text Add to dashboard Cite

This research investigates how the term "insight" was employed in 25 decisions from mental health review proceedings in Victoria, Australia. The application of insight appears problematic in these decisions. First, there is little clarification of its meaning. Second, the logic applied when insight is related to compliance is often unclear. Third, there are frequent allusions to an implicit and undefined scale of insight, offering the appearance of objectivity. We have analysed insight as an 'interpretive resource', focusing on its various functions in the complex social context of commitment hearings and with a view to its therapeutic jurisprudence implications. The variable application of insight-its interpretive flexibility-appears useful in addressing complex problems faced by review boards. Hence, a key function of insight is to bridge between legal and clinical discourses. Insight is also a convenient means to avoid complicated debates regarding the person's credibility. By analysing insight in Victoria, we hope to contribute to better theoretical understanding of decision-making patterns in mental health law in general.

show abstract

The range of therapeutic efficacy of atypical antipsychotics: a critical evaluation

Cited by 7 publications

References 35 publications

Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?

Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?

Open‐label steady‐state pharmacokinetic drug interaction study on co‐administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder

Interpretive flexibility: why doesn't insight incite controversy in mental health law?

Contact Info

Product

Resources

About